Lunit plans to highlight clinical trial results to be presented at the 2023 World Conference on Lung Cancer in Singapore that show AI analysis of tertiary lymphoid structures can predict treatment response in non-small cell lung cancer patients.
The study was conducted by Lunit researchers in collaboration with teams from Ascension Saint Francis Hospital in Evanston, IL; Lincoln Medical and Mental Health Center in the Bronx, New York; and Northwestern University Feinberg School of Medicine in Chicago. The study has explored the efficacy of Lunit's artificial intelligence biomarker platform, Lunit SCOPE IO -- an AI-supported hematoxylin and eosin analyzer which identifies tertiary lymphoid structures within the tumor microenvironment -- to predict lung cancer immunotherapy treatment outcomes.
The study included 85 patients with non-small cell lung cancer who received immune checkpoint inhibitors. Researchers found that using Lunit SCOPE IO to evaluate tertiary lymphoid structures demonstrated clinically significant correlations with patients' overall survival, Lunit said.
